These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15644587)

  • 1. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.
    Noguchi Y; Tatsuno I; Suyama K; Shibata T; Yoshida T; Otsuka Y; Fuse M; Takeo C; Saito Y
    J Atheroscler Thromb; 2004; 11(6):335-40. PubMed ID: 15644587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
    Li LJ; Chen H; Ren JY; Wang L; Luo Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
    J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
    Kiortsis DN; Elisaf MS
    Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
    Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
    Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
    Steinmetz J; Morin C; Panek E; Siest G; Drouin P
    Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases.
    Ka T; Inokuchi T; Tsutsumi Z; Takahashi S; Moriwaki Y; Yamamoto T
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):22-6. PubMed ID: 16425967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
    Elisaf M; Tsimichodimos V; Bairaktari E; Siamopoulos KC
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):60-3. PubMed ID: 10413068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
    Waldman B; Ansquer JC; Sullivan DR; Jenkins AJ; McGill N; Buizen L; Davis TME; Best JD; Li L; Feher MD; Foucher C; Kesaniemi YA; Flack J; d'Emden MC; Scott RS; Hedley J; Gebski V; Keech AC;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):310-318. PubMed ID: 29496472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
    Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
    Takahashi S; Moriwaki Y; Yamamoto T; Tsutsumi Z; Ka T; Fukuchi M
    Ann Rheum Dis; 2003 Jun; 62(6):572-5. PubMed ID: 12759298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fenofibrate on serum uric acid levels.
    Liamis G; Bairaktari ET; Elisaf MS
    Am J Kidney Dis; 1999 Sep; 34(3):594. PubMed ID: 10469875
    [No Abstract]   [Full Text] [Related]  

  • 15. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fenofibrate on uric acid metabolism and urate transporter 1.
    Uetake D; Ohno I; Ichida K; Yamaguchi Y; Saikawa H; Endou H; Hosoya T
    Intern Med; 2010; 49(2):89-94. PubMed ID: 20075570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
    Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
    Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
    Rozza F; Trimarco V; Izzo R; Grassi D; Ferri C
    High Blood Press Cardiovasc Prev; 2016 Dec; 23(4):381-386. PubMed ID: 27644242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
    Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.